William T Creasman1, Shamshad Ali2, David G Mutch3, Richard J Zaino4, Matthew A Powell5, Robert S Mannel6, Floor J Backes7, Paul A DiSilvestro8, Peter A Argenta9, Michael L Pearl10, Shashikant B Lele11, Saketh R Guntupalli12, Steven Waggoner13, Nick Spirtos14, John F Boggess15, Robert P Edwards16, Virginia L Filiaci17, David S Miller18. 1. Department of Obstetrics & Gynecology, Medical University of South Carolina, Charleston, SC 29425, United States. Electronic address: creasman@musc.edu. 2. NRG Oncology/Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. 3. Division of Gynecologic Oncology, Washington University School of Medicine, Saint Louis, MO 63110, United States. Electronic address: mutchd@wudosis.wustl.edu. 4. Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, United States. Electronic address: rzaino@psu.edu. 5. Division of Gynecologic Oncology, Washington University School of Medicine, Saint Louis, MO 63110, United States. Electronic address: mpowell@wustl.edu. 6. Department of Gynecologic Oncology, The Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States. Electronic address: robert-mannel@ouhsc.edu. 7. Division of Gynecologic Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United States. Electronic address: floor.backes@osumc.edu. 8. Department of Gynecologic Oncology, Women and Infants Hospital, Providence, RI 02905, United States. Electronic address: pdisilvestro@wihri.org. 9. Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical Center-Fairview, Minneapolis, MN 55455, United States. Electronic address: argenta@umn.edu. 10. Department of Obstetrics, Gynecology and Reproductive Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, United States. Electronic address: michael.pearl@sbumed.org. 11. Department of Gynecology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: shashi.lele@roswellpark.org. 12. Department of Gynecologic Oncology, University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, CO 80045, United States. Electronic address: saketh.guntupalli@ucdenver.edu. 13. Department of Obstetrics & Gynecology, Case Western Reserve University, Cleveland, OH 44106, United States. Electronic address: steven.waggoner@uhhospitals.org. 14. Division of Gynecologic Oncology, Women's Cancer Center of Nevada, Las Vegas, NV 89169, United States. Electronic address: nspirtos@wccenter.com. 15. Department of Gynecology Oncology, University of North Carolina at Chapel Hill, Raleigh, NC 27607, United States. Electronic address: jboggess@med.unc.edu. 16. Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, United States. Electronic address: edwarp@mail.magee.edu. 17. NRG Oncology/Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: gfiliaci@gogstats.org. 18. Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. Electronic address: david.miller@utsouthwestern.edu.
Abstract
OBJECTIVE: To report clinical and pathologic relationships with disease spread in endometrial cancer patients. METHODS: Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who were eligible to participate in a surgical pathological study to create a clinically annotated tissue biorepository to support translational and clinical research studies. All patients were to undergo a hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy. From 2003-2007, open eligibility enrollment was conducted, and from 2007-2011, eligibility was restricted to enrich underrepresented patients or those at high risk. RESULTS: This report details clinical pathological relationships associated with extra uterine disease spread of 5866 evaluable patients including those with endometrioid histology as well as papillary serous, clear cell and carcinosarcoma histologies. Review of unrestricted enrollment was constructed in an effort to capture a cross-section population representative of endometrial cancers seen by the GOG participating members. Evaluation of this group of patients suggested the more natural incidence of different surgical pathological findings as well as demographic information. The addition of 2151 patients enrolled during the restricted time interval allowed a total of 1630 poor histotype patients available for further analysis. As expected, endometrioid (E) cancers represented the largest enrollment and particularly E grade 1 and 2 (G1 and 2) were more frequently confined to the uterus. Grade 3 (G3) endometrioid cancers as well as the poor histotype (papillary serous, clear cell and carcinosarcoma) had a much greater propensity for extant disease. CONCLUSIONS: This study confirms the previously reported surgical pathological findings for endometrioid cancers but in addition, using a large database of papillary serous, clear cell and carcinosarcoma, surgical pathological findings substantiate the categorization of poor histotypes for these cancers.
OBJECTIVE: To report clinical and pathologic relationships with disease spread in endometrial cancerpatients. METHODS: Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who were eligible to participate in a surgical pathological study to create a clinically annotated tissue biorepository to support translational and clinical research studies. All patients were to undergo a hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy. From 2003-2007, open eligibility enrollment was conducted, and from 2007-2011, eligibility was restricted to enrich underrepresented patients or those at high risk. RESULTS: This report details clinical pathological relationships associated with extra uterine disease spread of 5866 evaluable patients including those with endometrioid histology as well as papillary serous, clear cell and carcinosarcoma histologies. Review of unrestricted enrollment was constructed in an effort to capture a cross-section population representative of endometrial cancers seen by the GOG participating members. Evaluation of this group of patients suggested the more natural incidence of different surgical pathological findings as well as demographic information. The addition of 2151 patients enrolled during the restricted time interval allowed a total of 1630 poor histotype patients available for further analysis. As expected, endometrioid (E) cancers represented the largest enrollment and particularly E grade 1 and 2 (G1 and 2) were more frequently confined to the uterus. Grade 3 (G3) endometrioid cancers as well as the poor histotype (papillary serous, clear cell and carcinosarcoma) had a much greater propensity for extant disease. CONCLUSIONS: This study confirms the previously reported surgical pathological findings for endometrioid cancers but in addition, using a large database of papillary serous, clear cell and carcinosarcoma, surgical pathological findings substantiate the categorization of poor histotypes for these cancers.
Authors: Veronica Wendy Setiawan; Hannah P Yang; Malcolm C Pike; Susan E McCann; Herbert Yu; Yong-Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S Weiss; Penelope M Webb; Piet A van den Brandt; Koen van de Vijver; Pamela J Thompson; Brian L Strom; Amanda B Spurdle; Robert A Soslow; Xiao-ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E Rohan; Kim Robien; Harvey A Risch; Fulvio Ricceri; Timothy R Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H Olson; Kirsten B Moysich; Anthony B Miller; Marjorie L McCullough; Rayna K Matsuno; Anthony M Magliocco; Galina Lurie; Lingeng Lu; Jolanta Lissowska; Xiaolin Liang; James V Lacey; Laurence N Kolonel; Brian E Henderson; Susan E Hankinson; Niclas Håkansson; Marc T Goodman; Mia M Gaudet; Montserrat Garcia-Closas; Christine M Friedenreich; Jo L Freudenheim; Jennifer Doherty; Immaculata De Vivo; Kerry S Courneya; Linda S Cook; Chu Chen; James R Cerhan; Hui Cai; Louise A Brinton; Leslie Bernstein; Kristin E Anderson; Hoda Anton-Culver; Leo J Schouten; Pamela L Horn-Ross Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544
Authors: John K Chan; Vera Loizzi; Mark Youssef; Kathryn Osann; Joanne Rutgers; Steven A Vasilev; Michael L Berman Journal: Gynecol Oncol Date: 2003-07 Impact factor: 5.482
Authors: C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan Journal: Br J Cancer Date: 2006-03-13 Impact factor: 7.640
Authors: Minsi Zhang; T Jonathan Yang; Neil B Desai; Deborah DeLair; Marisa A Kollmeier; Vicky Makker; Mario M Leitao; Nadeem R Abu-Rustum; Kaled M Alektiar Journal: Brachytherapy Date: 2018-10-10 Impact factor: 2.362
Authors: Koji Matsuo; Shinya Matsuzaki; David J Nusbaum; Hiroko Machida; Yoshikazu Nagase; Brendan H Grubbs; Lynda D Roman; Jason D Wright; Philipp Harter; Maximilian Klar Journal: Eur J Cancer Date: 2020-05-17 Impact factor: 9.162
Authors: Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2020-04-01 Impact factor: 5.482
Authors: Koji Matsuo; David J Nusbaum; Shinya Matsuzaki; Erica J Chang; Lynda D Roman; Jason D Wright; Philipp Harter; Maximilian Klar Journal: Gynecol Oncol Date: 2020-07-18 Impact factor: 5.482
Authors: Gloria S Huang; Marc J Gunter; Melissa A Merritt; Howard D Strickler; Alan D Hutson; Mark H Einstein; Thomas E Rohan; Xiaonan Xue; Mark E Sherman; Louise A Brinton; Herbert Yu; David S Miller; Nilsa C Ramirez; Heather A Lankes; Michael J Birrer Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02-23 Impact factor: 4.090
Authors: Koji Matsuo; Hiroko Machida; Andrea Mariani; Rachel S Mandelbaum; Gretchen E Glaser; Bobbie S Gostout; Lynda D Roman; Jason D Wright Journal: J Gynecol Oncol Date: 2018-05-04 Impact factor: 4.401